Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 | Zendy

Ji Miao | Zendy; Praveen V. Manthena | Zendy; Mary E. Haas | Zendy; Alisha V. Ling | Zendy; DongJu Shin | Zendy; Mark J. Graham | Zendy; Rosanne M. Crooke | Zendy; Jingwen Liu | Zendy; Sudha B. Biddinger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9

Author(s) -

Ji Miao,

Praveen V. Manthena,

Mary E. Haas,

Alisha V. Ling,

DongJu Shin,

Mark J. Graham,

Rosanne M. Crooke,

Jingwen Liu,

Sudha B. Biddinger

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.305688

Subject(s) - pcsk9 , kexin , proprotein convertase , insulin , endocrinology , medicine , ldl receptor , insulin receptor , biology , lipoprotein , cholesterol , insulin resistance

Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor and targets it for degradation, has emerged as an important regulator of serum cholesterol levels and cardiovascular disease risk. Although much work is currently focused on developing therapies for inhibiting PCSK9, the endogenous regulation of PCSK9, particularly by insulin, remains unclear. The objective of these studies was to determine the effects of insulin on PCSK9 in vitro and in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research